Correlation Between Pmv Pharmaceuticals and Blueprint Medicines

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pmv Pharmaceuticals and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pmv Pharmaceuticals and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pmv Pharmaceuticals and Blueprint Medicines Corp, you can compare the effects of market volatilities on Pmv Pharmaceuticals and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pmv Pharmaceuticals with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pmv Pharmaceuticals and Blueprint Medicines.

Diversification Opportunities for Pmv Pharmaceuticals and Blueprint Medicines

0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Pmv and Blueprint is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Pmv Pharmaceuticals and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Pmv Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pmv Pharmaceuticals are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Pmv Pharmaceuticals i.e., Pmv Pharmaceuticals and Blueprint Medicines go up and down completely randomly.

Pair Corralation between Pmv Pharmaceuticals and Blueprint Medicines

Given the investment horizon of 90 days Pmv Pharmaceuticals is expected to under-perform the Blueprint Medicines. But the stock apears to be less risky and, when comparing its historical volatility, Pmv Pharmaceuticals is 1.38 times less risky than Blueprint Medicines. The stock trades about -0.15 of its potential returns per unit of risk. The Blueprint Medicines Corp is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  8,682  in Blueprint Medicines Corp on December 29, 2024 and sell it today you would earn a total of  291.00  from holding Blueprint Medicines Corp or generate 3.35% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Pmv Pharmaceuticals  vs.  Blueprint Medicines Corp

 Performance 
       Timeline  
Pmv Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Pmv Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Blueprint Medicines Corp 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating primary indicators, Blueprint Medicines may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pmv Pharmaceuticals and Blueprint Medicines Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Pmv Pharmaceuticals and Blueprint Medicines

The main advantage of trading using opposite Pmv Pharmaceuticals and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pmv Pharmaceuticals position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.
The idea behind Pmv Pharmaceuticals and Blueprint Medicines Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies